Prudential Financial Inc. Decreases Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Prudential Financial Inc. decreased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,243 shares of the company’s stock after selling 100 shares during the period. Prudential Financial Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $2,479,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TEVA. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company’s stock worth $165,461,000 after buying an additional 801,106 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in Teva Pharmaceutical Industries Limited by 150.7% in the fourth quarter. UBS Asset Management Americas Inc. now owns 2,004,760 shares of the company’s stock worth $72,672,000 after buying an additional 1,205,253 shares in the last quarter. State of Wisconsin Investment Board boosted its position in Teva Pharmaceutical Industries Limited by 0.8% in the first quarter. State of Wisconsin Investment Board now owns 1,952,150 shares of the company’s stock worth $62,644,000 after buying an additional 15,140 shares in the last quarter. American Century Companies Inc. boosted its position in Teva Pharmaceutical Industries Limited by 7.2% in the first quarter. American Century Companies Inc. now owns 1,791,707 shares of the company’s stock worth $57,496,000 after buying an additional 120,041 shares in the last quarter. Finally, AGF Investments Inc. boosted its position in Teva Pharmaceutical Industries Limited by 5.7% in the first quarter. AGF Investments Inc. now owns 1,549,244 shares of the company’s stock worth $49,673,000 after buying an additional 84,133 shares in the last quarter. 56.19% of the stock is owned by hedge funds and other institutional investors.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 0.34% during midday trading on Friday, reaching $32.34. The company had a trading volume of 4,046,745 shares. Teva Pharmaceutical Industries Limited has a 52-week low of $27.60 and a 52-week high of $55.79. The company’s 50-day moving average is $31.96 and its 200-day moving average is $32.34. The firm has a market cap of $32.86 billion, a P/E ratio of 414.62 and a beta of 0.47.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The firm had revenue of $5.63 billion during the quarter, compared to the consensus estimate of $5.69 billion. During the same period last year, the business posted $1.20 EPS. The business’s revenue was up 17.0% compared to the same quarter last year. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.75 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Prudential Financial Inc. Decreases Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/07/29/prudential-financial-inc-decreases-stake-in-teva-pharmaceutical-industries-limited-nyseteva-updated-updated-updated.html.

TEVA has been the subject of a number of analyst reports. Vetr upgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $36.12 price target for the company in a report on Monday, April 3rd. Cowen and Company reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, April 4th. BTIG Research reaffirmed a “neutral” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, April 6th. Oppenheimer Holdings, Inc. set a $43.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research report on Thursday, April 6th. Finally, CIBC reaffirmed a “buy” rating and issued a $43.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, April 7th. Fifteen investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $42.88.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply